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Summary 
Eighty-four patients (6 IIB, 57 IIIA, 21 IIIB) were recruited to IDEAL-CRT, an early 
phase trial of dose-per-fraction-escalated concurrent chemoradiation for NSCLC. 
Tumor doses of 63-73Gy (mean 67.6Gy) were isotoxically prescribed to the ICRU 
reference-point and delivered in 30 fractions over 40 days. Toxicity was acceptable. 
At 35 months median follow-up, median OS was 36.9 months, 1 year OS and PFS 
were 87.8% and 72.0%, and 2 year OS and PFS were 68.0% and 48.5%.     
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Abstract 
Background and Purpose  
Toxicity and early efficacy data are presented for IDEAL-CRT, a trial of an escalated, 
concurrent chemoradiotherapy schedule for advanced stage non-small cell lung 
cancer (NSCLC). Tumor dose-per-fraction-escalation was used in IDEAL-CRT to 
achieve therapy intensification without prolongation, and tumor doses were 
prescribed isotoxically to maximum levels consistent with normal tissue dose 
constraints. 
Patients and Methods  
Patients received tumor doses of 63-73Gy in 30 once-daily fractions over 6 weeks 
with two concurrent cycles of cisplatin and vinorelbine. They were assigned to one of 
two groups according to esophageal dose. In Group 1, tumor doses were determined 
by an experimental constraint on maximum esophageal dose which was escalated 
following a 6+6 design from 65Gy through 68Gy to 71Gy, allowing an esophageal 
maximum tolerated dose (MTD) to be determined from early and late toxicities. 
Tumor doses for Group 2 patients were determined by other tissue constraints, often 
lung. Overall survival (OS), progression-free survival (PFS), tumor response and 
toxicity were evaluated for both groups combined. 
Results 
Eight centres recruited 84 patients: 13, 12 and 10 in the 65Gy, 68Gy and 71Gy 
cohorts of Group 1, and 49 in Group 2. The mean prescribed tumor dose was 
67.6Gy. Five grade 3 esophagitis and three grade 3 pneumonitis events were 
observed across both groups. Following one fatal esophageal perforation in the 71Gy 
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cohort, 68Gy was declared the esophageal MTD. With a median follow-up of 35 
months, median OS was 36.9 months, and OS and PFS were 87.8% and 72.0% at 1 
year and 68.0% and 48.5% at 2 years.  
Conclusions 
IDEAL-CRT achieved significant treatment intensification with acceptable toxicity and 
promising survival. The isotoxic design allowed the esophageal MTD to be identified 
from relatively few patients. 
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Introduction 
Intensification of local treatment has been associated with increased local control 
and overall survival (OS) for non-small cell lung cancer (NSCLC) patients. Improved 
2-year OS was reported for CHART trial patients treated using 54Gy delivered in just 
12 days compared to the standard 60Gy in 40 days (29% versus 20%)1, while a 
recent meta-analysis has reported a hazard ratio (HR) of 0.86 for intensification of 
radiation-only or sequential chemo-radiotherapy (CRT) treatments compared to 
control arms2. A meta-analysis of trials of concurrent versus sequential CRT found 
an advantage for concurrent delivery of radiation and chemotherapy, with an HR of 
0.77 for local progression-free survival (PFS) and 5.7% and 4.5% absolute benefit in 
OS at 3 and 5 years3. 
RTOG 0617 recently examined the effect of increasing radiotherapy (RT) tumor 
doses from 60 to 74Gy given in five 2Gy fractions per week4. Unexpectedly, survival 
was significantly lower in the 74Gy arm, perhaps partly because the 11 day increase 
in total treatment time required for additional fractions reduced the effectiveness of 
tumor dose-escalation. Dose-per-fraction-escalation circumvents this by fixing the 
number of fractions and treatment duration, hypofractionating and effectively 
accelerating RT5-7. It may therefore provide a more effective means of local 
treatment intensification8–10. 
RT toxicity is determined by doses delivered to normal tissues. Early phase trials 
testing the toxicity of intensified CRT or RT combined with novel agents should 
control these normal tissue doses, while allowing prescribed tumor doses to vary 
within an acceptable range. Isotoxic dose-escalation accomplishes this by 
prescribing the highest deliverable tumor doses without exceeding pre-determined 
normal tissue limits. 
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We report toxicity and early survival data for IDEAL-CRT, a trial of tumor dose-
escalated concurrent CRT for NSCLC. Dose-per-fraction-escalation was used to 
achieve intensification without schedule protraction; tumor doses were prescribed 
isotoxically; and selected patients were prospectively assigned to cohorts receiving 
incrementally increasing esophageal RT doses. 
Patients and methods 
This non-randomized phase I/II trial enrolled stage II and III NSCLC patients, who 
received tumor RT doses between 63Gy and 73Gy in 30 once-daily fractions over 40 
days, concurrent with two cycles of cisplatin and vinorelbine.  
Patients 
Inclusion criteria were histologically/cytologically confirmed stage IIA-IIIB NSCLC, 
WHO performance status (PS) 0-1, suitability for CRT agreed by multidisciplinary 
team, no prior anti-cancer therapy, forced expiratory volume (FEV1) ≥40% predicted 
or ≥1L, carbon monoxide diffusing capacity (DLCO) ≥40% predicted, hematology and 
biochemistry baselines suitable for chemotherapy, and glomerular filtration rate ≥60 
ml/min. Patients with chronic liver disease and/or bilirubin >35µmol/l, connective 
tissue disorders (e.g. scleroderma, systemic lupus) or history of prior malignancy 
likely to interfere with protocol treatment were excluded. 
Design 
Patients received the highest prescribed tumor doses between 63-73Gy deliverable 
while meeting the normal tissue dose constraints shown in Table 1. For lungs, spinal 
cord, brachial plexus and heart these constraints were held at levels determined 
from an earlier review11. However, insufficient data linking dose to toxicity existed for 
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an esophageal constraint to be defined up-front, and so an incrementally increasing 
esophageal limit was used during the trial. To facilitate this process, patients were 
split after RT treatment planning but before tumor dose prescription into two non-
randomized groups based on dosimetric findings. In Group 1, prescribed tumor 
doses were limited by an escalating esophageal constraint, while in Group 2 
prescribed tumor doses were limited by lung and other normal tissue constraints. 
Allocation of patients to these groups was therefore determined purely on the basis 
of dosimetry and not clinician choice.  
Group 1 was designed as a phase I study to establish an esophageal maximum 
tolerated dose (MTD), patients’ prescribed tumor doses being limited by an 
escalating experimental constraint on dose delivered to the most highly irradiated 
1cc of esophagus. This esophageal dose constraint was progressively raised from 
65Gy to 68Gy and then 71Gy following a 6+6 design (Supplementary Figure 1), 
treating 6 or 12 patients at each level. It was initially planned to include a 73Gy 
esophageal dose cohort, but the 73Gy upper limit on prescribed tumor dose meant 
that in practice it was not feasible to deliver 73Gy to 1cc of oesophagus. Dose-
limiting toxicities (DLTs) were grade ≥3 esophagitis (CTCAE v4.0) occurring during 
or within 4 weeks of completing RT and late esophageal toxicity which was 
monitored closely. 
Group 2 comprised all trial patients whose prescribed tumor doses were limited by 
other dose constraints, often lung or cord, and was designed to provide further 
toxicity data, particularly for radiation pneumonitis (RTPN). For some Group 2 
patients, however, prescribed tumor dose was limited by a lower esophageal 
constraint, already known to be safe, initially set at 63Gy to 1cc (Table 1). As the trial 
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recruited, this Group 2 esophageal limit was progressively raised to levels for which 
early toxicity had been found to be acceptable in cohorts of 12 patients in Group 1.  
Feasibility and survival data were analyzed jointly across both groups, comprising 
the phase II element of the study.  
Interventions 
Concurrent chemotherapy was 2 cycles of i.v. cisplatin 75 mg/m2 on days 1 and 29 
of RT, and i.v. vinorelbine 15 mg/m2 on days 1, 8, 29 and 36. No induction or 
consolidation chemotherapy was allowed. 
RT planning was the same for Groups 1 and 2.  3D- or 4D-CT images were collected  
during quiet breathing, and on 3D-CT images the gross tumor volume (GTV) was 
contoured and then expanded by 5mm to create a clinical target volume (CTV), and 
by a further 5mm minimum radial and 10mm minimum cranio-caudal to form a 
planning target volume (PTV). On 4D-CT a composite volume was formed by 
merging GTVs outlined on the different scan phases, then expanded by 5mm to form 
a CTV and by 5mm minimum further in all directions to form a PTV. Most patients 
were treated using 3D conformal plans comprising 3-5 photon fields of energy 5-
8MV. Some were treated using volumetric modulated arc therapy (VMAT), according 
to available centre resources. Dose-distributions were calculated using ‘type-b' 
superposition-convolution algorithms12 and all tumor doses were prescribed to 
the International Commission on Radiation Units (ICRU) reference-point.  
The tumor dose prescription process is summarized in Table 1. For each patient an 
initial prescribed tumor dose was selected to achieve a target value of 18.2Gy for 
lung EQD2mean, the average equivalent dose in 2Gy fractions delivered to all CT 
voxels of both lungs excluding the GTV13,14. This level is associated with a 20% rate 
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of Southwest Oncology Group (SWOG) G2-5 RTPN and a presumed G3-5 rate of 
<10%13,15. The prescribed tumor dose was then reduced by 10% to allow for toxicity 
caused by concurrent chemotherapy, and further if necessary to meet the tabulated 
dose constraints for esophagus, brachial plexus, heart and spinal cord11. If this 
caused the prescribed tumor dose to fall below the trial minimum of 63Gy, the lung 
EQD2mean limit was relaxed to 19.3Gy, and the patient would still receive a prescribed 
tumor dose of 63Gy provided this relaxed lung limit and all the other normal tissue 
constraints listed in Table 1 could be met. Prescribed tumor doses were capped at 
73Gy to limit damage to central blood vessels and airways. 
Quality assurance was overseen by the Radiotherapy Trials Quality Assurance 
Group of the National Cancer Research Institute. Before starting the trial, clinicians 
and physicists from each centre attended an outlining and dose prescription 
workshop.  Clinicians outlined two benchmark cases16 which were checked against 
contours drawn by the Principal Investigator, and planned two pre-outlined 
benchmark cases which were reviewed to ensure that trial dosimetric aims were met. 
An additional arc-planned case was checked for centres introducing VMAT. 
Equipment details were collected via an on-line questionnaire. Contouring and 
dosimetry of each centre’s first recruited case was independently reviewed prior to 
treatment. Further reviews were requested, where deemed necessary, to ensure 
protocol compliance. Subsequently all treatment plan data was collected centrally 
and analyzed retrospectively to verify conformance to the trial protocol. 
Staging CT of the thorax and abdomen and PET scanning were performed for all 
patients, either one within 42 days of commencing RT. Clinical assessments of PS, 
hematology, weight and dyspnoea score were made weekly during RT. Post-
treatment PS, weight, dyspnoea score, pulmonary function, adverse events and 
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toxicity data were collected at clinical reviews held weekly during the first month, 
monthly to 6 months, 3-monthly to 24 months, 6-monthly to 36 months and annually 
thereafter. CT thorax and abdomen and lung function tests were carried out 3, 6, 12 
and 24 months after completion of RT, chest x-ray at 1, 3, 6, 12, 18 and 24 months, 
and ECG at 6 and 12 months. 
Outcomes and statistics 
Trial endpoints were toxicity, particularly grade 3-5 esophagitis and grade 2-5 RTPN, 
OS, PFS and tumor response (RECIST version 1.1). Attribution of toxicity to 
treatment was overseen by an independent data monitoring committee. OS and PFS 
rates were estimated using Kaplan-Meier methods. All patients who received at least 
one fraction of RT were included in this analysis. The database cut-off date was July 
31st 2015.  
The Group 1 sample size depended on toxicity seen: up to 36 patients were 
possible, 12 each in the three feasible cohorts. In Group 2, assuming a G2-5 RTPN 
rate of 20% was of further interest, 45 patients were required to exclude an 
unacceptable rate of 40% with a 1-sided 5% significance level and 90% power17.  
Role of the funding source 
The funder, Cancer Research UK, was not involved in the conduct, analysis or 
interpretation of the trial, or the writing of this paper. The trial sponsor, responsible 
for trial conduct and analysis, was University College London. The corresponding 
author had full access to all the data in the study and final responsibility to submit for 
publication. The trial was run in accordance with the Declaration of Helsinki and with 
the approval of all relevant ethical bodies and regulatory authorities. 
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Results 
Between September 2010 and March 2013, 84 patients from eight UK centres were 
enrolled, 35 in Group 1 and 49 in Group 2, with the baseline characteristics shown in 
Table 2.  Of these, 34 patients (40.5%) were planned using 4DCT and 50 (59.5%) 
with intravenous contrast. Three patients were treated using VMAT. An extra patient 
was recruited to the 65Gy cohort of Group 1 as re-planning during treatment was 
required for one of the patients initially recruited, adding uncertainty to the delivered 
maximum esophageal dose. Twelve patients were recruited to the 68Gy cohort of 
Group 1 but only ten to 71Gy before trial funding ended (Figure 1).  
Two patients in Group 2 did not begin treatment following clinical deterioration. Of 
the 82 patients starting CRT, 81 (98.8%) completed both cycles of chemotherapy 
and 81 (97.6%) received all 30 RT fractions (Figure 1): one patient withdrew due to 
toxicity (Group 2). Median relative dose intensity was 99.6% for cisplatin and 99.0% 
for vinorelbine, and RT was generally delivered as scheduled with a median duration 
of 5.6 weeks (range 5.1-6.6 weeks, Supplementary Table 1). Prescribed tumor 
doses are shown in Figure 2 and have an overall mean of 67.7Gy, with means of 
68.9Gy and 66.8Gy for Groups 1 and 2 respectively. 
Toxicity 
Grade 2-5 RTPN was seen in 30.5% of patients who received trial treatment (1-sided 
upper 95% confidence limit: 39.9%; 2-sided 95% confidence interval (CI): 20.8-
41.6%). Three of these RTPN events were Grade 3 (3.7%, 95% CI: 0.8-10.3%). 
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The Grade 2-5 esophagitis rate overall was 82.9% (2-sided 95% CI: 73.0-90.3%), 
with five Grade 3 toxicities (6.1%, 2-sided 95% CI: 2.0-13.7%). A fatal esophageal 
perforation occurred in one patient in the 71Gy cohort of Group 1, 7 months post-RT 
(Table 3), and was considered directly related to treatment. The esophageal MTD 
was therefore set at 68Gy to 1cc of esophagus. 
A further three patients had fatal events, (Table 3), all hemoptysis. One occurred 14 
months post-RT with tumor recurrence and was considered possibly treatment-
related (Group 1, prescribed tumor dose 72.6Gy); another at 4.5 months post-RT 
with residual tumor was considered unrelated (Group 2, prescribed tumor dose 
68.5Gy); and the third at 4 weeks post-RT was also considered unrelated (Group 2, 
prescribed tumor dose 67.6Gy). 
Incidences of esophagitis and RTPN are listed by grade and trial group in Table 3, 
alongside a summary of other toxicities. Rates of other complications are listed in 
more detail in Supplementary Table 2, whilst the latency of Grade 3-5 toxicities is 
summarized in Supplementary Table 3. Supplementary Table 4 summarizes the trial 
dosimetrically, listing prescribed tumour doses for all three cohorts of Group 1 and 
for Group 2, alongside details of delivered doses to the constrained normal tissues.  
Efficacy  
At the 3 months post-RT visit, 52 patients (63.4%) had a partial response, 21 
(25.6%) stable disease, 4 (4.9%) had progressive disease, 4 (4.9%) had non-
evaluable disease and 1 (1.2%) patient had died.  
After a median follow-up of 34.9 months (range: 2.2-51.2) there were 40 deaths, the 
remaining 42 patients being censored at the last date known to be alive. One- and 
two-year OS was 87.8% (95% CI: 80.7-94.9%) and 68.0% (95% CI: 57.8-78.1%), 
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and median OS was 36.9 months (95% CI: 31.7-42.1 months) (Figure 3a). OS is 
plotted by tumor stage in Figure 3b. Figure 3c shows OS for the 82 patients split into 
two subgroups having prescribed tumor doses greater or less than the 68Gy median; 
the risk of death was lower for the higher tumor dose subgroup (HR=0.53, 95% CI: 
0.28-1.02, p=.06). There were 49 PFS events overall. One- and two-year PFS was 
72.0% (95% CI: 62.2-81.7%) and 48.5% (95% CI: 37.6-59.3%), and median PFS 
was 21.1 months (95% CI: 11.5-30.6 months) (Figure 3d).  
Discussion 
IDEAL-CRT tested a novel, individualized, tumor-dose-per-fraction-escalated 
concurrent CRT schedule for NSCLC. The trial demonstrated acceptable toxicity, 
feasibility and promising clinical outcomes as well as defining an esophageal MTD 
for the schedule.  
The 6% rate of G3-5 esophagitis in IDEAL-CRT is lower than the 18% and 25% 
average rates found in two meta-analyses of concurrent CRT3,18, and the 7%, 19% 
and 26% rates of the two dose arms of RTOG 06174 and the MAASTRO study of 
isotoxically individualized concurrent CRT10. Intensive clinical input resulting from 
mandated weekly patient assessments may have reduced the number of G3-5 cases 
in IDEAL-CRT, and the study’s dosimetric focus may also have limited esophageal 
irradiation. 
There was one late G3-5 esophageal toxicity, a fatal perforation in the 71Gy cohort 
of trial Group 1, and 68Gy was defined as the esophageal MTD. Of 171 patients 
treated using concurrent CRT at Netherlands Cancer Institute (NKI), Amsterdam, 
three suffered esophageal fistula and eight grade 3 stenosis19. In the high dose arm 
of RTOG 0617 three of 206 patients died of gastro-intestinal (GI) toxicity20 and an 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
additional nine of 442 patients overall experienced late grade 3-5 GI toxicity4. The 
most significant predictor of late esophageal toxicity in the NKI series was 
esophageal volume receiving an EQD2 ≥76.7Gy. Using the linear-quadratic model 
with an α/β ratio of 3Gy to account for fractionation differences14, this equates to the 
71Gy esophageal dose-level of the IDEAL-CRT cohort in which the esophageal 
perforation occurred.  
The ability of the isotoxic escalation scheme to limit the incidence of RTPN was 
confirmed by the G2-5 RTPN and G3-5 RTPN rates of 30.5% (95% CI: 20.8-41.6%) 
and 3.7% (95% CI: 0.8-10.3%) respectively in the patients who received trial 
treatment, similar to the 7% and 4% G3-5 rates of the control and escalated arms of 
RTOG 0617, and the 7% rate in the Cochrane review of concurrent CRT18. A 
detailed analysis of possible associations between dosimetry, observed pulmonary, 
cardiac and esophageal toxicities and survival is underway. 
Two deaths in IDEAL-CRT were treatment-related. In the Cochrane review 
treatment-related deaths were recorded in 3% of patients receiving concurrent 
CRT18. In RTOG 0617, eight treatment-related deaths occurred in the 74Gy group 
versus seven in the 60Gy group, and ten patients receiving cetuximab had 
treatment-related deaths versus five not receiving cetuximab4. Overall, despite 
substantial treatment intensification, toxicity in IDEAL-CRT does not appear higher 
than in other relevant concurrent CRT studies. 
IDEAL-CRT patients were recruited and treated at multiple sites, supported by a 
rigorous quality assurance program21. Their demographics and tumor characteristics 
were roughly comparable to those of patients in previous studies (Table 2)3,4. The 
average prescribed tumor dose of 67.7Gy in 30 fractions corresponds to a 15% 
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increase in EQD2 above the 60Gy dose given in 30 fractions in the control arm of 
RTOG0617, assuming a 10Gy α/β ratio for NSCLC14,15. While it remains to be 
proven in randomized trials whether this degree of intensification improves survival, 
the 36.9 month median OS seen in IDEAL-CRT is promising and compares well with 
median OS times of 28.7 and 20.3 months in the control and escalated arms of 
RTOG 0617, and with 24.3 months in the concurrent CRT arm of the UK SOCCAR 
trial4,22. 
The relatively high survival seen in IDEAL-CRT may originate from strict adherence 
to the CRT protocol, as well as from treatment intensification. It might also reflect the 
stage-mix of patients (7% stage IIB, more stage IIIA than IIIB), although we found no 
evidence of a difference in OS between IIIA and IIIB patients (HR=1.23; 95% 
CI:0.59-2.57; p=0.58) (Figure 3b). The borderline-significant survival advantage seen 
for patients treated with prescribed doses greater than the median could be 
interpreted as showing an increase in tumor control either with rising dose or with 
falling tumor size, since isotoxic schemes tend to prescribe higher doses to smaller 
tumors. 
A key feature of IDEAL-CRT was its focus on doses to organs-at-risk, particularly in 
determining the safety of progressively increasing esophageal doses in a sequence 
of patient cohorts. While it is not possible to plan exactly the same RT dose-
distribution in each patient, we have nevertheless demonstrated the feasibility of 
structured patient recruitment to cohorts defined by key dosimetric predictors of 
toxicity. This aspect of trial design proved to be effective and efficient in 
prospectively identifying an MTD for esophagus using relatively few patients, and is 
highly relevant to early phase studies investigating intensified RT across many tumor 
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types and sites, and to studies exploring the addition to RT of systemic therapies, 
radiosensitizers or radioprotectors.  
Conclusions 
Toxicity results and survival data from IDEAL-CRT are promising. Dose-limits have 
been determined efficiently using the study’s approach to dose-escalation, namely 
by incrementally increasing key dose-metrics in specific normal tissues. We have 
recently completed recruitment to a 5-week form of the IDEAL-CRT schedule, 
designed to further limit tumor repopulation during treatment, and are presently 
planning a randomized trial of the 6-week schedule described here versus standard 
dose CRT. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
References 
1. Saunders M, Dische S, Barrett A, et al: Continuous hyperfractionated accelerated 
radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung 
cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 
350:161–5, 1997 
2. Yamoah K, Showalter TN, Ohri N: Radiation therapy intensification for solid 
tumors: A systematic review of randomized trials. Int. J. Radiat. Oncol. Biol., Phys. 
93: 737-745, 2015  
3. Auperin A, Le Pechoux C, Rolland E, et al: Meta-analysis of concomitant versus 
sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. 
Clin. Oncol. 28:2181–90, 2010 
4. Bradley JD, Paulus R, Komaki R, Masters G, et al. Standard-dose versus high-
dose conformal radiotherapy with concurrent and consolidation carboplatin plus 
paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell 
lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet 
Oncol. 16:187-99, 2015. 
5. Mauguen A, Le Pechoux C, Saunders MI, et al: Hyperfractionated or accelerated 
radiotherapy in lung cancer: an individual patient data meta-analysis. J. Clin. Oncol. 
30:2788–97, 2012 
6. Salama JK, Vokes EE: New radiotherapy and chemoradiotherapy approaches for 
non-small-cell lung cancer. J. Clin. Oncol. 31:1029–38, 2013 
7. Machtay M, Bae K, Movsas B, et al: Higher biologically effective dose of 
radiotherapy is associated with improved outcomes for locally advanced non-small 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
cell lung carcinoma treated with chemoradiation: an analysis of the Radiation 
Therapy Oncology Group. Int. J. Radiat. Oncol., Biol., Phys. 82:425–34, 2012 
8. Van Baardwijk A, Bosmans G, Bentzen SM, et al: Radiation dose prescription for 
non-small cell lung cancer according to normal tissue dose constraints: an in silico 
clinical trial. Int. J. Radiat. Oncol., Biol., Phys.  71:1103–10, 2008 
9. De Ruysscher D, van Baardwijk A, Steevens J, et al: Individualised isotoxic 
accelerated radiotherapy and chemotherapy are associated with improved long-term 
survival of patients with stage III NSCLC: a prospective population-based study. 
Radiother. Oncol. 102:228–33, 2012. 
10. Van Baardwijk A, Reymen B, Wanders S, et al: Mature results of a phase II trial 
on individualised accelerated radiotherapy based on normal tissue constraints in 
concurrent chemo-radiation for stage III non-small cell lung cancer. Eur. J. Cancer. 
48:2339–46, 2012 
11. Fenwick JD, Nahum AE, Malik ZI, et al: Escalation and intensification of 
radiotherapy for stage III non-small cell lung cancer: opportunities for treatment 
improvement. Clin. Oncol. 21:343–60, 2009 
12. Knöos T, Wieslander E, Cozzi I, et al: On the dosimetric behaviour of photon 
dose calculation algorithms for treatment planning in external photon beam therapy 
for clinical situations. Phys. Med. Biol. 51:5785–807, 2006.  
13.  De Jaeger K, Hoogemans MS, Engelsman M, et al: Incorporating an improved 
dose-calculation algorithm in conformal radiotherapy of lung cancer: re-evaluation of 
dose in normal lung tissue. Radiother. Oncol. 69:1–10, 2003. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
14 Joiner MC, Bentzen SM: Dose-response relationships in radiotherapy. In: Steel 
GG, ed. Basic Clinical Radiobiology. London: Arnold, 126, 2002. 
15. Mehta M, Scrimger R, Mackie R, et al: A new approach to dose escalation in 
non-small-cell lung cancer. Int. J. Radiat. Oncol., Biol., Phys. 49:23–33, 2001 
16. Melidis C, Bosch WR, Izewska J, et al: Global harmonization of quality 
assurance naming conventions in radiation therapy clinical trials.  Int. J. Radiat. 
Oncol., Biol., Phys. 90: pp. 1242-1249, 2014 
17. A'Hern RP. Sample size tables for exact single-stage phase II designs. Statist. 
Med. 20:859-866, 2001     
18. O’Rourke N, Roqué i Figuls M, Bernadó NF, et al: Concurrent 
chemoradiotherapy in non-small cell lung cancer. (Review). The Cochrane Library, 
(6) 2010. 
19. Chen C, Uyterlinde W, Sonke J-J, et al: Severe late esophagus toxicity in 
NSCLC patients treated with IMRT and concurrent chemotherapy. Radiother. Oncol 
108: 337-41, 2013. 
20. A randomized phase III comparison of standard-dose (60Gy) versus high-dose 
(74Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-
small cell lung cancer: Results on radiation dose in RTOG 0617. 
http://meetinglibrary.asco.org/content/82285?media=vm 
21. Parsons E, Lester J, Hughes L, Miles E, et al: Can dose escalation be 
consistently carried out in a multi-centre trial? QA results for IDEAL-CRT and I-
START trials. Abstract. Radiother. Oncol. 115:S121;2015 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
22.  Maguire J, Khan I, McMenemin R, O'Rourke N, et al. SOCCAR: A randomised 
phase II trial comparing sequential versus concurrent chemotherapy and radical 
hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung 
cancer and good performance status. Eur. J. Cancer 50:2939-49 2014. 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
                                             Tables & Figures 
Figure 1: CONSORT diagram.  
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  Table 1: Summary of the RT planning and dose prescription process. 
Process steps 
Tumor coverage aim 
PTV 90% isodose to cover 98% of PTV 
Tumor dose prescribed to the ICRU reference-point initially selected to achieve  
Lung EQD2mean 18.2Gy 
Prescribed tumor dose reduced by 10%, and further if needed to meet the limits 
Heart D100% <45Gy, D67% <53Gy, D33% <60Gy 
Spinal Cord D0.1cc  ≤47Gy 
Brachial plexus D30% ≤60Gy, D0.1cc ≤65Gy 
Esophagus Dose to1cc   
= 65Gy 
Dose to 1cc  
= 68Gy 
Dose to 1cc  
= 71Gy 
Dose to 1cc  
≤ 63Gy* 
Limit for Group 1 Group 1 Group 1 Group 2 
Prescribed tumor dose finally limited to 63-73Gy, patients being ineligible for the trial if this 
causes lung V20Gy** or EQD2mean to exceed 35% or 19.3Gy respectively. 
  Equivalent dose in 2Gy fractions averaged across lung excluding gross tumor volume (GTV). 
 DX[%or cc] denotes the minimum dose delivered to the most highly irradiated X% or X cc of the tissue. 
* This dose-level increased to 65Gy, and then 68Gy as safety data became available from Group 1. 
** V20Gy is the volume of lung excluding GTV receiving more than 20Gy. 
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Table 2: Demographics and baseline characteristics of all patients. 
  Group 1 
(N= 35) 
Group 2 
(N= 49) 
Total 
(N=84) 
Age (# patients) > 70  10 (29%) 13 (27%) 23 (27%) 
 (years) < 70  25 (71%) 36 (74%) 61 (73%) 
 Mean (SD) 65.6 (8.0) 65.4 (8.0) 65.5 (8.0) 
 Median (range) 66 (46-84) 66 (43-78) 66 (43-84) 
     
Gender Female 9 (26%) 13 (27%) 22 (26%) 
  Male 26 (74%) 36 (73%) 62 (74%) 
      
WHO PS 0 12 (34%) 20 (41%) 32 (38%) 
  1 23 (66%) 29 (59%) 52 (62%) 
     
Histology Adenocarcinoma 12 (34%) 14 (29%) 26 (31%) 
  Squamous 17 (49%) 30 (61%) 47 (56%) 
  Other NSCLC 6 (17%) 5 (10%) 11 (13%) 
     
Stage IIA 
         0  0  0  
 IIB 
         0  6 (12%) 6 (7%) 
 IIIA 
         24 (69%)        33 (67%)   57 (68%) 
 IIIB 
         11 (31%)        10 (20%) 21 (25%) 
     
GTV size  Mean (SD) 127.7 (118.9) 118.0 (83.3) 122.1 (99.4) 
(cm3) Median (range) 110 (14-602) 92 (15-329) 109 (14-602) 
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Table 3: Selected toxicities by grade amongst the 82 patients who began RT 
(safety population), according to trial group. 
Toxicity  Grade Group 1 
(N=35) 
Group 2 
(N=47) 
Total 
(N=82) 
  
   
Esophagitis 0 2 (6%) 7 (15%) 9 (11%) 
 1 1 (3%) 4 (9%) 5 (6%) 
 2 30 (86%) 33 (70%) 63 (77%) 
 3 2 (6%) 3 (7%) 5 (6%) 
 4 0 0 0 
 5 0 0 0 
  
   
RTPN$ 0 11 (31%) 24 (51%) 35 (43%) 
  1 12 (34%) 10 (21%) 22 (27%) 
  2 10 (29%) 12 (26%) 22 (27%) 
  3 2 (6%) 1 (2%) 3 (4%) 
 4 0 0 0 
 5 0 0 0 
All toxicities grades ≥ 3  25 (71%) 36 (77%) 61 (74%) 
 
3 20 (57%) 26 (55%) 46 (56%) 
 4 3 (9%) 8 (17%) 11 (13%) 
  5 2 (6%) 2 (4%) 4 (5%) 
  
   
Grade ≥ 3% Hematological 
 
  
 
White Blood Cell Decreased      2 (6%) 9 (19%) 11 (13%) 
Lymphocyte Decreased   1 (3%) 8 (17%) 9 (11%) 
Neutrophil Decreased  4 (11%) 8 (17%) 12 (15%) 
Grade ≥ 3 Other 
   
 
 Lung Infection  9 (26%) 9 (19%) 18 (22%) 
 FEV Decreased  5 (14%) 7 (15%) 12 (15%) 
$
 RTPN = radiotherapy pneumonitis. Two patients received higher lung doses than allowed in the 
protocol. Both received prescribed tumor doses of 63Gy, one with a lung V20 of 46.5% and one with 
40.7%. Neither experienced RTPN. 

 Four patients had grade 5 events: In Group 1, one patient experienced esophageal perforation and 
one hemoptysis. Two Group 2 patients experienced hemoptysis.  

 There were no relevant hemoglobin-related events. 
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